Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia

Phase 1

Terminated

Conditions: Stage I Chronic Lymphocytic Leukemia
Stage III Chronic Lymphocytic Leukemia
Leukemia
Prolymphocytic Leukemia
Stage IV Chronic Lymphocytic Leukemia
B-cell Chronic Lymphocytic Leukemia
Stage II Chronic Lymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia

Interventions: Drug: obatoclax mesylate
Drug: fludarabine phosphate
Biological: rituximab
Other: laboratory biomarker analysis

First Posted Date: 2008-02-11

Last Posted Date: 2013-09-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 28

Registration Number: NCT00612612

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma

Phase 2

Terminated

Conditions: Metastatic Melanoma
Skin Cancer

Interventions: Biological: autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes
Biological: ALVAC MART-1 Vaccine
Biological: aldesleukin
Drug: cyclophosphamide
Drug: fludarabine phosphate

First Posted Date: 2008-02-11

Last Posted Date: 2015-10-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 4

Registration Number: NCT00612222

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma

Phase 2

Terminated

Conditions: Metastatic Melanoma
Skin Cancer

Interventions: Drug: cyclophosphamide
Drug: fludarabine phosphate
Biological: Aldesleukin
Biological: ALVAC gp100 Vaccine

First Posted Date: 2008-02-07

Last Posted Date: 2015-10-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3

Registration Number: NCT00610311

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma

Phase 3

Completed

Conditions: Lymphoma

First Posted Date: 2008-02-06

Last Posted Date: 2013-08-26

Lead Sponsor: Taunton and Somerset Hospital

Target Recruit Count: 400

Registration Number: NCT00608374

Locations: 🇦🇺
Princess Alexandra Hospital, Brisbane, Queensland, Australia
🇦🇺
Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
🇬🇧
Bradford Royal Infirmary, Bradford, England, United Kingdom

and more 45 locations

Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil

Not Applicable

Terminated

Conditions: Graft Versus Host Disease
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes

Interventions: Biological: anti-thymocyte globulin
Drug: cyclophosphamide
Drug: fludarabine phosphate
Radiation: total-body irradiation
Drug: methylprednisolone

First Posted Date: 2008-02-06

Last Posted Date: 2014-05-20

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 6

Registration Number: NCT00608517

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Veterans Affairs Medical Center - Nashville, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States

and more 1 locations

T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer

Phase 1

Completed

Conditions: Leukemia
Multiple Myeloma
Lymphoma
Plasma Cell Neoplasm
Myelodysplastic Syndromes

Interventions: Biological: umbilical cord blood transplantation
Drug: Allopurinol
Drug: fludarabine phosphate
Drug: Cyclophosphamide
Radiation: Total body irradiation
Biological: Treg infusion
Drug: Sirolimus

First Posted Date: 2008-01-28

Last Posted Date: 2017-12-02

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 41

Registration Number: NCT00602693

Locations: 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Stage II Chronic Lymphocytic Leukemia
Stage I Chronic Lymphocytic Leukemia
Stage III Chronic Lymphocytic Leukemia
Stage IV Chronic Lymphocytic Leukemia

Interventions: Drug: Fludarabine Phosphate
Drug: Cyclophosphamide
Other: Laboratory Biomarker Analysis
Biological: Rituximab
Drug: Lenalidomide

First Posted Date: 2008-01-28

Last Posted Date: 2023-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 418

Registration Number: NCT00602459

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Grant Medical Center, Columbus, Ohio, United States
🇺🇸
Mount Carmel Health Center West, Columbus, Ohio, United States

and more 361 locations

Hematopoietic Stem Cell Transplantation for Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using Total Body Irradiation, Cyclophosphamide and Fludarabine

Not Applicable

Completed

Conditions: Fanconi Anemia

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Radiation: Total body irradiation (TBI)

First Posted Date: 2008-01-16

Last Posted Date: 2016-08-10

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 21

Registration Number: NCT00595127

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies

Phase 2

Terminated

Conditions: Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Myelodysplasia
Chronic Myeloid Leukemia

Interventions: Radiation: Total Body Irradiation
Drug: Thiotepa
Drug: Fludarabine
Biological: Rabbit ATG
Drug: Palifermin

First Posted Date: 2008-01-15

Last Posted Date: 2018-04-10

Lead Sponsor: Sherif S. Farag

Target Recruit Count: 9

Registration Number: NCT00593554

Locations: 🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States

In-Vivo Activated T-Cell Depletion to Prevent GVHD

Not Applicable

Terminated

Conditions: Myelodysplasia
Myelofibrosis
Acute Myelogenous Leukemia
Chronic Myelogenous Leukemia
Chronic Lymphocytic Leukemia
Multiple Myeloma
Acute Lymphocytic Leukemia
Mantle-Cell Lymphoma
Lymphoma, Non-Hodgkin's
Hodgkin's Disease

First Posted Date: 2008-01-15

Last Posted Date: 2014-10-06

Lead Sponsor: Indiana University

Target Recruit Count: 10

Registration Number: NCT00594308

Locations: 🇺🇸
Indiana Universtiy Simon Cancer Center, Indianapolis, Indiana, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy